Sharemaestro Newsreel

Tilray Brands (NASDAQ:TLRY) Trading Up 2.9% - Should You Buy?

Tilray Brands (NASDAQ:TLRY) shares increased by 2.9% to $4.57 during mid-day trading, though volume was below average. The stock remains below its 200-day moving average, and while analyst sentiment is mixed, it leans towards a "Moderate Buy" with an $11.00 price target. The company …

United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise

United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares at $135.42 and subsequently sold these shares through a family trust in multiple transactions ranging from $512.50 to $532.3932 per share. These transactions, executed on August 6, 2026, were part …

Anika Therapeutics, Inc. (ANIK) Stock Price, News, Quote & History

This article provides comprehensive financial data for Anika Therapeutics, Inc. (ANIK), including its current stock price, historical performance, and key financial metrics. It details the company's orthopedic products and services, analyst ratings, and comparative data with other companies in the drug manufacturing industry. The …

Director grant at Cronos Group Inc. (CRON) adds deferred share units

Cronos Group Inc. director James Daniel Rudyk was granted 48,859.9300 Deferred Share Units (DSUs) on August 6, 2026, bringing his total direct holdings to 362,742.2200 DSUs. These DSUs entitle him to a lump-sum cash payment equal to the fair market value of a Cronos …

Cronos Group Inc. (CRON) director receives deferred share unit award

Cronos Group Inc. director Jason Marc Adler was granted 48,859.93 Deferred Share Units, bringing his total holdings to 362,742.22 units. These units are cash-settled based on the fair market value of Cronos Group common shares upon redemption, which occurs after he ceases to be …

Deferred share unit grant for Cronos Group Inc. (CRON) director Garnick

Cronos Group Inc. director Murray R. Garnick was granted 48,859.93 Deferred Share Units on August 6, 2026. These units are cash-settled, meaning upon redemption, Garnick will receive a cash payment equal to the fair market value of Cronos common shares. Following this grant, his …

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Tilray Brands (TLRY) counsel buys 2500 shares, holdings now 124883

Tilray Brands' Global General Counsel, Gendel Mitchell, purchased 2,500 shares of common stock at $4.43 per share on August 6, 2026. This transaction increased his direct holdings to 124,883 shares. The purchase, valued at $11,000, was reported in a Form 4 SEC filing and …

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands (TLRY) recently reported its Q4 and full-year 2026 results, showing increased sales of US$915.45 million and a significantly reduced net loss of US$121.4 million. The company also filed a US$47.69 million shelf registration for its ESOP and indicated plans for future acquisitions …

Tilray Brands Inc. stock rises Friday, outperforms market

Tilray Brands Inc. (TLRY) saw its stock rise by 2.93% on Friday, closing at $4.57. This performance outpaced the broader market, with the NASDAQ Composite Index gaining 1.30% and the Dow Jones Industrial Average rising 0.28%. This marks the second consecutive day of gains …

Talphera Inc (TLPH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Talphera Inc (TLPH) has an earnings forecast score of 8.00, placing it 58th in the Pharmaceuticals industry. Analysts have set an average price target of $3.50, with a range from $3.00 to $6.00, and a "Buy" rating based on three analysts' opinions. The company's …

SIGA TECHNOLOGIES INC 2Q 2026: Revenue $41M, EPS $0.17— 10-Q Summary

SIGA TECHNOLOGIES INC reported its Q2 2026 results with revenue of $41 million and diluted earnings per share of $0.17, both significantly down from the prior-year quarter due to shifts in product mix and lower U.S. oral TPOXX® deliveries. The company's business remains heavily …

ANIK (NASDAQ: ANIK) holder plans Form 144 sale of 16,864 shares

An individual holder of Anika Therapeutics, Inc. (ANIK) plans to sell 16,864 shares of common stock on NASDAQ, with an aggregate market value of $355,255.47 as of August 7, 2026, according to a Form 144 filing. The filing also notes recent activity including an …

Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open

Teva Pharmaceutical Industries (TEVA) has raised its 2026 revenue outlook and confirmed mid-single-digit revenue growth targets for 2027, despite reporting a net loss in the second quarter. The stock has seen significant momentum, with a 113.69% return over the last year, leading to a …

Amylyx Pharmaceuticals (AMLX) Could Be 5% Undervalued After Second Quarter Earnings

Canopy Growth 1Q Rev C$81.2M >WEED.T

Canopy Growth (WEED.T) reported its first-quarter revenue, reaching C$81.2 million. This financial update provides key insights into the company's performance during the quarter. The >WEED.T symbol indicates its listing on the Toronto Stock Exchange.

IM Cannabis (Nasdaq: IMCC) raises $250K in convertible note financing

IM Cannabis Corp. (Nasdaq: IMCC) has secured US$250,000 in convertible note financing from an institutional investor, issuing a note and a warrant for up to 2,052,545 common shares. The company received net proceeds of US$225,000, which will be used for general corporate purposes. The …

Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket

ANI Pharmaceuticals reported stronger-than-expected Q2 2026 results, with adjusted EPS of $2.21 and record revenue of $266 million, surpassing analyst estimates. Despite the beat, the stock fell in premarket trading due to investor focus on the company's outlook, declining gross margins, and a revised …

Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences announced inducement grants of stock options and restricted stock units (RSUs) to seven new employees. These grants, totaling 19,850 stock options and 11,000 RSUs, were made outside the company's existing equity incentive plans as an inducement material to the new hires' employment …

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast …

RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026

RedHill Biopharma Ltd. announced that all resolutions proposed at its adjourned Annual General Meeting of Shareholders on August 7, 2026, were duly approved. This includes the re-appointment of auditors, re-election of board members, approval of Dror Ben-Asher as Chairman and CEO, and an amendment …

Rockwell Medical, Inc. (RMTI) stock price, news, quote and history

This article provides a comprehensive overview of Rockwell Medical, Inc. (RMTI) stock, including its current price, historical data, and key financial metrics. It details the company's operations in developing and distributing hemodialysis products and features analyst insights, including a recent price target increase by …

Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases

Evotec SE and Odyssey Therapeutics Inc. have announced a strategic AI-enabled R&D collaboration aimed at discovering new small molecule treatments for autoimmune and inflammatory diseases. The partnership combines Odyssey's disease biology expertise with Evotec's integrated discovery platform, advanced screening technologies, and proprietary compound libraries. …

CSE Filings for Optimi Health Corp.

This page from the Canadian Securities Exchange (CSE) provides access to regulatory filings for Optimi Health Corp. (OPTI). It details the company's active status, industry (Life Sciences), issued and outstanding shares, and offers various filtering options to search through different types of CSE and …

Quantinno Capital Management LP Sells 168,471 Shares of Perrigo Company plc $PRGO

Quantinno Capital Management LP reduced its stake in Perrigo Company plc by 25.4%, selling 168,471 shares and retaining 493,866 shares valued at approximately $5.3 million. Despite a decline in sales, Perrigo's latest quarterly earnings beat expectations, and the company reaffirmed its fiscal 2026 EPS …

ANI Pharmaceuticals Releases Q2 2026 Financial Results

ANI Pharmaceuticals, Inc. reported strong Q2 2026 financial results, with adjusted diluted EPS of $2.21, beating analyst estimates, and revenue of $266.0M, a 25.9% increase year-over-year. The company's flagship product, Cortrophin Gel, was a key growth driver, and management provided optimistic full-year EPS guidance. …

Prestige Consumer Healthcare Inc (PBH) (Q1 2027) Earnings Call Highlights: Record Cash Flow and ...

Prestige Consumer Healthcare Inc. (PBH) reported exceeding sales and earnings expectations in Q1 fiscal 2027, with total sales up 6.5% to $266 million and record adjusted free cash flow of $83.7 million. The company successfully integrated the Breathe Right acquisition and completed another strategic …

Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Trulieve Cannabis Corp. 2026 Q2 - Results - Earnings Call Presentation (NYSE:TRLV) 2026-08-07

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...

This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Record Q2 2026 revenues of $266 million, up 26% year-over-year, driven by strong performance in …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …

Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts

Akebia Therapeutics (AKBA) stock fell 26% to US$0.95 following a Q2 2026 earnings report showing revenue decline and a net loss, raising concerns about its valuation. While the company's Vafseo product is showing strong growth, the overall revenue fall and decline in Auryxia sales, …

HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating Hims & Hers Health, Inc. (NYSE:HIMS) following a lawsuit filed by the FTC and California alleging violations of federal securities laws and unlawful business practices. The lawsuit claims Hims & Hers failed to disclose prescription charges, made …

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also …